Telix Pharmaceuticals Limited (TLX) Fair Value 2026

TLX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.2 /10

32 fundamental signals · 7 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-28, Telix Pharmaceuticals Limited (TLX) trades at $11.29, versus a $2.44 median fair value across its 7 active models — 78.4% below the current price. QOC: 7.2/10. Value Trap Risk: 0/100 (SAFE). 7/13 models active. Within that set, the Bayesian DCF component alone returns $3.54.

Key Facts

Ticker
TLX
Price
$11.29
Quality Score
7.2/10
Value Trap Risk
0/100
Models Active
7/13
Last Updated
Strength: 7 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Telix Pharmaceuticals Limited (TLX) Undervalued or Overvalued in 2026?

According to CirclFi’s 7-model valuation engine, Telix Pharmaceuticals Limited (TLX) appears overvalued as of : the median of 7 independent fair value estimates is $2.44, 78.4% below the current price of $11.29. Estimates range from $1.21 to $3.54. TLX scores 7.2/10 on fundamental quality and 0/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. TLX’s -78.4% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Telix Pharmaceuticals Limited Stock in 2026? →

What Fair Value Does Each Model Give TLX?

7 Intrinsic Value Models vs. Current Price ($11.29)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $3.54 -68.6%
Ensemble · Low Conviction
 $2.54 -77.5%
Scenario · Medium Conviction
 $3.05 -72.9%
Unlock the Full Matrix

Access 4 additional models including Regime Cross-Sectional, Sentiment SOTP, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 7 Models →

Cancel anytime · No contracts · Instant access

What Is TLX's Fair Value Range?

Spread across 7 independent models · $1.21 to $3.54

CirclFi's 7 active models place Telix Pharmaceuticals Limited (TLX) between $1.21 and $3.54 per share, a spread of 96% of the median. The median of that range — $2.44 — is the fair value CirclFi publishes for TLX, against a current price of $11.29.

Low · Regime CrossHigh · Bayesian DCF
$1.21median $2.44$3.54
Where the range comes from
Most bearish modelRegime Cross-Sectional$1.21
Most bullish modelBayesian DCF$3.54
Model agreement0 bullish · 7 bearishmoderate

A band of this width is typical. The methods agree on direction but weight growth, reinvestment and risk differently, so treat the median as a centre of gravity rather than a precise target.

Every figure above is one model's standalone output on TLX, not a CirclFi price target. How each model works →

What Is Telix Pharmaceuticals Limited (TLX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Telix Pharmaceuticals Limited's intrinsic value is estimated at $2.44. Trading at its current price of $11.29, the valuation engine raises significant caution: 7 of 7 models flag downside risk, projecting a median implied return of -78.4%.

What Do the Models Say About TLX?

7 of 13 models are currently active for TLX. All 7 active models suggest the stock trades above fair value. Taken together, their median fair value for TLX is $2.44 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $3.54 on its own, implying -68.6% downside from the current price. See which stocks rank higher →

How Does TLX Rank in Biotechnology?

Among 625 Biotechnology stocks, TLX ranks #39 by Quality of Company score. CirclFi's QOC score of 7.2/10 evaluates 32 fundamental signals. A score of 7.2 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotechnology enterprise businesses. For Telix Pharmaceuticals Limited, metrics like R&D burn rate provide important context that general-purpose valuation models may underweight.

Is TLX a Value Trap?

CirclFi's Value Trap algorithm assigns TLX a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

7 of 13 models are active for Telix Pharmaceuticals Limited. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Telix Pharmaceuticals Limited earns a quality score of 7.2/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

Models cluster within a tight range (+20.7% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every TLX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across TLX's 7 active models, average confidence is 34%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Telix Pharmaceuticals Limited Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

BNTXBioNTech SEQOC 7.3ARVNArvinas, Inc.QOC 7.2SPROSpero Therapeutics, Inc.QOC 7.4ARCTArcturus Therapeutics Holdings Inc.QOC 7.2BDTXBlack Diamond Therapeutics, Inc.QOC 7.5SRPTSarepta Therapeutics, Inc.QOC 7.1IVAInventiva S.A.QOC 5.6PLYXPolaryx Therapeutics, Inc.QOC 4.9RVPHReviva Pharmaceuticals Holdings, Inc.QOC 4.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: BNTX · ARVN · SPRO · ARCT · BDTX · SRPT · IVA · PLYX · RVPH · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to TLX?

7 companies across all industries closest to TLX’s Quality of Company score of 7.2/10.

ELANElanco Animal Health IncorporatedQOC 7.2DOCHealthpeak Properties, Inc.QOC 7.2QNTOQuaint Oak Bancorp, Inc.QOC 7.2RRyder System, Inc.QOC 7.2AMCXAMC Global Media Inc.QOC 7.2INDVIndivior Pharmaceuticals, Inc.QOC 7.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ELAN · DOC · QNTO · R · AMCX · INDV · NVDA

Where Does TLX Sit in CirclFi's Biotechnology Rankings?

TLX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Telix Pharmaceuticals Limited’s Valuation?

What is Telix Pharmaceuticals Limited's intrinsic value in 2026?

CirclFi puts Telix Pharmaceuticals Limited (TLX)'s intrinsic value at $2.44 — the median of 7 independent model estimates as of 2026-08-28, ranging from $1.21 to $3.54. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $3.54 on its own. The Quality of Company score is 7.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is TLX overvalued or undervalued right now?

At $11.29, 0 of 7 active models suggest TLX may be undervalued, while 7 indicate potential overvaluation. The median of all 7 fair value estimates is $2.44, 78.4% below the current price of $11.29 — a consensus view that TLX is overvalued. The assessment depends on which methodology best fits Telix Pharmaceuticals Limited's business model in Biotechnology.

What does a Quality of Company score of 7.2 mean for TLX?

Telix Pharmaceuticals Limited's QOC of 7.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on TLX?

CirclFi analyzes TLX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 7 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on TLX?

Of the 7 models currently active on TLX, Bayesian DCF is the most bullish at $3.54 per share, and Regime Cross-Sectional is the most bearish at $1.21. CirclFi's published fair value for TLX is the median of that range, $2.44, not either extreme. The gap between the two ends equals 96% of the median — a normal spread for a company of this profile. Browse stocks by value-trap risk →

Is TLX a value trap in 2026?

Telix Pharmaceuticals Limited's Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 7-model valuation engine, Telix Pharmaceuticals Limited (TLX) has a median fair value of $2.44 — 78.4% below the current price of $11.29 — as of 2026-08-28.” Source: circlfi.com/stock/TLX/ · Methodology
Primary sources for this TLX valuation
  • Financial statements: Telix Pharmaceuticals Limited 10-K and 10-Q filings on SEC EDGAR (CIK 0002007191) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for TLX as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 7 mathematical frameworks give you clarity on TLX.

Unlock All 7 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for TLX Unlock All 7 — $39/mo